Testing two lung cancer drugs for returning or advanced NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests almonertinib plus SHR-1701 in people whose non-small cell lung cancer has returned or is advanced. The goal is to see how well the combination works and whether it is safe for participants with measurable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign consent and join willingly
- You’re 18–75 years old, and your lung cancer is advanced or has come back after standard treatment
- You have at least one tumor spot that can be measured on scans
- Your overall health score is 0–1 (you can do most daily activities)
- You must not have certain major conditions, including untreated brain symptoms from spread or serious uncontrolled fluid buildup
- You must not have recent serious infections, uncontrolled heart or blood pressure problems, or recent bleeding/heavy coughing blood
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
This trial tests a combination of two drugs, Almonertinib and Lastet, for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) that cannot be removed by surgery or cured with radiation and chemotherapy. The goal is to see if the combination works better than standard treatments.
Hear when a new Relapsed or Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.